Australia markets closed
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • AUD/USD

    0.7487
    -0.0064 (-0.85%)
     
  • OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD

    1,763.90
    -10.90 (-0.61%)
     
  • BTC-AUD

    47,903.58
    -954.82 (-1.95%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • AUD/EUR

    0.6308
    -0.0028 (-0.44%)
     
  • AUD/NZD

    1.0787
    +0.0009 (+0.09%)
     
  • NZX 50

    12,551.93
    +10.73 (+0.09%)
     
  • NASDAQ

    14,049.58
    -114.22 (-0.81%)
     
  • FTSE

    7,017.47
    -135.96 (-1.90%)
     
  • Dow Jones

    33,290.08
    -533.37 (-1.58%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • Hang Seng

    28,801.27
    +242.68 (+0.85%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     

Global Gastroparesis Drugs Markets, 2012-2019 & 2020-2027: Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-Surgical Gastroparesis, Pharmacies, Clinics, e-Commerce - ResearchAndMarkets.com

·4-min read

The "Gastroparesis Drugs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Gastroparesis Drugs Market to Reach $7.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Gastroparesis Drugs estimated at US$5.3 Billion in the year 2020, is projected to reach a revised size of US$7.2 Billion by 2027, growing at a CAGR of 4.5% over the analysis period 2020-2027.

Diabetic Gastroparesis, one of the segments analyzed in the report, is projected to record a 4.5% CAGR and reach US$2.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Idiopathic Gastroparesis segment is readjusted to a revised 5.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.6 Billion, While China is Forecast to Grow at 4.2% CAGR

The Gastroparesis Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 4.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Post-Surgical Gastroparesis Segment to Record 3.1% CAGR

In the global Post-Surgical Gastroparesis segment, USA, Canada, Japan, China and Europe will drive the 3.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$641.9 Million in the year 2020 will reach a projected size of US$801 Million by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$804.4 Million by the year 2027.

Select Competitors (Total 47 Featured):

  • Abbott Laboratories

  • Allergan PLC

  • AstraZeneca PLC

  • Cadila Pharmaceuticals Ltd.

  • ETX Pharma, Inc.

  • Evoke Pharma, Inc.

  • GlaxoSmithKline PLC

  • Neurogastrx Inc.

  • Theravance Biopharma, Inc.

  • Valeant Pharmaceuticals International, Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • Influencer Market Insights

  • Impact of Covid-19 and a Looming Global Recession

  • World 15-Year Perspective for Gastroparesis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Diabetic Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Idiopathic Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Post-Surgical Gastroparesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

  • World 15-Year Perspective for E-Commerce by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 47

For more information about this report visit https://www.researchandmarkets.com/r/tp2tz8

View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005536/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting